Angiogenesis and Lymphangiogenesis in Bladder Cancer by Yasuyoshi Miyata et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
5 
Angiogenesis and Lymphangiogenesis  
in Bladder Cancer 
Yasuyoshi Miyata, Hideki Sakai and Shigeru Kanda 
Nagasaki University Graduate School of Biomedical Sciences 
Japan 
1. Introduction 
In cancer patients, the majority of deaths occur as a consequence of metastatic diseases. In 
addition, metastasis is a marker for poor prognosis and low quality of life in many 
malignancies. Several groups have investigated the mechanism of tumor metastasis. 
Metastatic lesions are formed through a multi-step complex process and then spread either 
locally at the site of the primary tumor, or into distant organs through the blood or 
lymphatic vessels. 
Another important feature of cancers is the chaotic behavior of tumor growth and cancer 
cell cycle progression. To maintain such activities, abundant supply of oxygen and nutrients 
are necessary. Angiogenesis refers to the formation of new blood vessels and development 
of new branching vessels from the existing tumor tissue vasculature and this pathological 
process is important to secure adequate blood supply including oxygen and nutrients to the 
rapidly dividing malignant cells. In fact, there is a good correlation between tumor 
growth/cancer cell proliferation and the extent of angiogenesis in almost of all cancers.  
While there is abundant information on the mechanisms that are involved in the initiation, 
regulation and maintenance of angiogenesis in cancer tissue, little is known about the 
mechanisms involved in the formation of new lymphatic vessels (lymphangiogenesis) in 
cancers. Furthermore, the current knowledge about cancer dissemination through the 
lymphatics lacks details about the mode of transport of cancer cells within the lymphatic 
vessels and the mechanisms involved in their exit and seeding into the distant organs. 
In this paper, we review the clinical and pathological significance of angiogenesis and 
lymphangiogenesis in bladder cancer. In addition, the mechanisms that regulate the 
formation of new vessels in bladder cancer are discussed. Specifically, we focus on the 
factors that co-regulate these two different vessels and their potential use as predictive 
marker of outcome in patients with bladder cancer. In addition, we also discuss the 
limitation of quantification of these vessels in human tissues.  
2. Angiogenesis and lymphangiogenesis  
2.1 Angiogenesis in cancer tissues 
Angiogenesis is defined as the formation of new blood vessels from pre-existing 
vasculature, and it is an integrated process of tumor growth, maintenance, and progression 
in solid tumors (Folkmann, 1992). Angiogenesis is a multistep processes involving changes 
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in the extracellular matrix, cell proliferation, cell migration, and tube formation. Blood 
vessel density (BVD), a surrogate marker for angiogenesis, correlates with the malignant 
potential and poor prognosis of patients with various types of cancers. In addition, anti-
angiogenic therapy that targets the tumor vascular supply and pathways of cancer cell 
dissemination was first introduced in 1971 (Folkman, 1971). Since then, numerous 
investigators have focused on the mechanisms of angiogenesis, including molecular 
mechanisms. At present, there is a general agreement that the regulation of tumor 
angiogenesis depends on a complex mechanism that dynamically balances angiogenic and 
anti-angiogenic factors. In this regard, these factors are secreted by both tumor cells and 
stromal cells in complicated systems. To complicate the issue, the mechanisms and 
pathological roles of these factors vary according to the type of cancer, its malignant 
potential, and systemic condition. 
2.2 Lymphangiogenesis in cancer tissues 
In addition to angiogenesis, many investigators have examined the process of 
lymphangiogenesis, i.e., the formation of new lymphatic vessels, due to its importance in 
lymph node metastasis and distant metastasis. Lymph node metastasis occurs in various 
types of malignancies and its presence is considered a strong predictor of recurrence and 
poor survival of patients with bladder cancer. However, the clinical role and prognostic 
value of lymphangiogenesis in cancer patients remain unclear, largely due to the lack of 
specific endothelial markers for lymphatic vessels as well as the lack of proper imaging 
procedures for lymphatic vessels in human tissues (Pepper, 2001). In recent years, various 
specific antibodies for lymphatic endothelial cells have been developed and used to 
investigate the clinical and pathological significance of lymphangiogenesis in cancer 
patients. Similar to angiogenesis, evidence suggests that lymphangiogenesis is also 
regulated by complex mechanisms that include a variety of factors. While various common 
mechanisms regulate the processes of angiogenesis and lymphangiogenesis, other 
mechanisms vary according to these processes. For example, in contrast to angiogenesis, no 
intrinsic anti-lymphangiogenic molecules have yet been isolated.  
Thus, to discuss the pathological roles, predictive values, and potential therapeutic targets 
of angiogenesis and lymphangiogenesis, it is important to understand the various complex 
mechanisms and cooperative functions involved in these two processes.  
2.3 Angiogenesis and lymphangiogenesis in bladder cancer 
BVD is often used in the analysis of human cancer tissues as a surrogate and semi-
quantitative marker of angiogenesis. Previous studies suggested that BVD provides 
significant information on prognosis and survival in patients with bladder cancer (Streeter & 
Harris, 2002; Goddard, 2003). However, other investigators were less supportive for the 
prognostic value of BVD, especially in patients with non-muscle-invasive bladder cancer 
(NMIBC) (Korkolopoulou, et al., 2001; Ioachim, et al., 2006; Miyata, et al., 2006). Table 1 
provides a summary of the currently held opposing views on BVD.  
Such discrepancy could be attributed to differences in methodology, such as methods used 
for counting, size of the field of view, definition of microvessel, and antibodies used in 
different assays. For example, measurement at periphery or growth from of the tumor 
(Stavropoulos et al., 2004) or at highest vascularity “hot spots” (Korkolopoulou et al., 2001). 
Furthermore, the diameter of the microvessel was no mentioned in some studies; though 
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other provided descriptive terms (the lumen diameter was smaller than approximately eight 
red blood cells) (Stavropoulos, 2004). More detailed problems are described in the following 
section.  
 
Patients Findings Reference 
109 NMIBC Predictor of muscle invasion in G3 patients, 
though not an independent factor. 
Starvropoulos 
66 NMIBC Independent predictor of recurrence-free 
survival, particularly in T1G2 tumors 
Santos 
35 NMIBC + 80 
MIBC 
Independent predictor for overall survival in 
MIBC. No significant role in NMIBC 
Korkolopoulou 
87 NMIBC + MIBC Independent predictor of lymph node metastasis. Susuki 
104 NMIBC + 22 
MIBC 
Not significant for recurrence-free, metastasis-
free, or cause-specific survival. 
Miyata 
NMIBC: non-muscle-invasive bladder cancer, MIBC: muscle-invasive bladder cancer 
Table 1. Predictive value of blood vessel density (BVD) for progression and survival. 
In addition to semi-quantitative measures of BVD, vascular invasion by tumor cells (blood 
vessel invasion, BVI) has also been identified as a prognostic factor in bladder cancer 
(Harada et al., 2005). Furthermore, vascular area and various parameters related to the 
shape, relapse, and/or complexity of the vessels have been suggested as important for more 
detailed discussion on the relationship between angiogenesis and pathological role, 
prognosis, and survival. In this regard, several investigators paid special attention to the 
morphological variability in the vascular pattern (Korkolopoulou et al., 2001; Sharma et al., 
2005), and one study reported that the vascular area was an independent predictor of overall 
survival in patients with T1 disease whereas BVD was not (Korkolopoulou et al., 2001).  
In contrast to angiogenesis, there is little or no information on the clinical and pathological 
significance and predictive value of lymphangiogenesis in patients with bladder cancer. 
Several studies reported that higher LVD correlates significantly with malignant behavior, 
cancer cell progression, and prognosis (Fernández et al., 2008; Miyata et al., 2006). In 
addition, one report indicated that the pathological role of lymphangiogenesis was 
depended on the location of lymphatic vessels, such as intra-tumoral and peri-tumoral area. 
In other words, intra-tumoral LVD correlated with histological differentiation, and peri-
tumoral LVD correlated with lymph node metastasis (Fernández, et al., 2008). Similar to 
BVI, of lymphatic vessel invasion (LVI) by tumor cells was also identified as a prognostic 
factor in bladder cancer (Algaba, 2006). In general, however, information on 
lymphangiogenesis in human bladder cancer is to a large extent scarce, compared to that on 
angiogenesis.  
2.4 Regulation of angiogenesis and/or lymphangiogenesis 
Members of the vascular endothelial growth factor (VEGF) family are the most important 
molecules involved in the processes of angiogenesis and lymphangiogenesis. This family 
consists of 7 members, including VEGF-A, -B, -C, -D, and -E, svVEGF, and placental growth 
factor. In addition, three types of receptors have so far been identified: VEGFR-1, -2, and -3 
(Takahashi et al., 2005). The angiopoietin (Ang) family also encompasses several pro-
angiogenic factors. This family consists of Ang-1 and -2 and Tie2 tyrosine kinase receptors, 
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and the system is influenced by VEGF family. In addition, several factors, for example, 
fibroblast growth factor (FGF)-2, hepatocyte growth factor (HGF), and insulin-like growth 
factor (IGF), are also reported to be involved in the regulation of both angiogenesis and 
lymphangiogenesis.  
Angiostatin and endostatin, which are both produced by proteolytic cleavage of 
plasminogen and collagen XVIII, respectively, are well characterized anti-angiogenic factors. 
(O’Reilly, et al., 1994, 1997). In addition, thrombospondins (TSPs) also inhibits angiogenesis 
(Lawler, 2000). Another report indicated that down-regulation of TSP-1 secretion in bladder 
cancer tissues was a key event in the change from an anti-angiogenic to an angiogenic 
phenotype during carcinogenesis (Campbell, et al., 1998). On the other hand, there are 
conflicting results on the relationship between TSP-1 expression and BVD in human bladder 
cancer. Specifically, TSP-1 staining correlated negatively with BVD (Grossdfeld et al., 1997), 
whereas other investigators reported that TSP-1 expression correlated positively with BVD 
(Ioachim et al., 2006).  
We review here in detail two representative pro-angiogenic factors; VEGF family and Ang 
family. Their selection was based on the finding that they are potential therapeutic targets in 
various cancers. Actually, targeted therapies based on these factors have been tested already 
in patients with bladder cancer. Unfortunately, however, anti-angiogenic factor-targeted 
therapy is still in its infancy and there is little possibility to use such drugs for treatment of 
bladder cancer in the near future.  
2.5 VEGF family 
Among the VEGF family members, VEGF-A is a major regulator of angiogenesis. On the 
other hand, both VEGF-C and VEGF-D have been found to play major roles in 
lymphangiogenesis. Furthermore, VEGFR-2 and VEGFR-3 are reported to be the major 
mediators of angiogenic response in blood endothelial cells and lymphangiogenic response 
in lymphatic endothelial cells, respectively. In other words, VEGF-A signaling through 
VEGFR-2 is the major pathway that activates angiogenesis by stimulating cell proliferation, 
survival, and migration of endothelial cells (Shibuya & Claesson-Welsh, 2006). Furthermore, 
the VEGF-C/D-VEGFR-3 signaling pathway is important for the growth of lymphatic 
endothelial cells (Skobe et al. 2001; Stacker et al., 2001; Lin, et al., 2005). In support of this 
notion, blocking the VEGF-C/D-VEGFR-3 signaling pathway was reported to inhibit tumor 
lymphangiogenesis and lymph node metastasis in several xenograft and transgenic tumor 
models (He et al., 2002; Lin et al., 2005; Roberts et al., 2006).  
In contrast to the above studies, several groups reported that VEGF-A could stimulate 
lymphangiogenesis in vivo (Nagy et al., 2002; Cursiefen et al., 2004). In addition, in an 
animal model of chemically-induced skin cancer, VEGF-A induced lymphangiogenesis and 
promoted lymphatic metastasis (Hirakawa et al., 2005). Conversely, VEGF-C and VEGF-D 
were reported to play important roles in angiogenesis under various physiological and 
pathological conditions (Cao 1998, Jussila & Alitalo, 2002).  
VEGFR-1 has a high affinity for VEGF-A, VEGF-B, and PIGF. However, its tyrosine kinase 
activity is comparatively weak (Autiero, et al., 2003; Shibutya & Claesson-Welsh, 2006). 
VEGFR-1 is expressed in endothelial cells. In addition, it is also expressed in 
monocytes/macrophages, hemopoietic cells, and pericytes. Its tyrosine kinase activity is 
required for stimulation of hemopoietic cell migration towards VEGFs and PIGFs (Barleon, 
et al., 1996; Clauss, et al. 1996). Based on these results, VEGF-B, PIGF, and VEGFR-1 are 
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thought to play minimal roles in angiogenesis. In fact, they do not activate angiogenesis 
during development. However, they have been reported to exhibit angiogenic activity 
under a variety of pathological conditions (Fisher et al., 2008). For examples, in animal 
experiments, PIGF was associated with angiogenesis in various pathological conditions 
including ischemia, inflammation, and tumor growth (Carmeliet, et al., 2001; Luttun, et al., 
2002).  
The role of VEGFR-2 in lymphangiogenesis is still controversial. VEHGR-2 is expressed at 
low levels in lymph vessels, and VEGF-VEGFR-2 signaling can induce lymphatic vessel 
formation (Hong et al., 2004). On the other hand, evidence suggests that lymphangiogenesis 
induced by such system involves the recruitment of immune cells producing VEGF-C and –
D (Crusiefen, et al., 2004). 
The following schematic diagram illustrates the relationship between VEGFs and VEGFRs 
and angiogenesis and lymphangiogenesis: 
 
 
2.6 VEGF family in bladder cancer 
Angiogenesis in bladder cancer involves the VEGF-A signaling through the receptor 
VEGFR-2. The interaction between VEGF-A and VEGFR-2 plays a crucial role in tumor 
growth, progression, and prognosis via regulation of angiogenesis in patients with bladder 
cancer. 
VEGF-C and –D are highly expressed in cancer cells than in normal urothelial cells 
(O’Breien, et al., 1995; Zu et al., 2006; Miyata, et al.). Several investigators have reported that 
the expression of VEGF-C in bladder cancer is closely associated with tumor progression 
including lymph node metastasis (Suzuki, et al., 2005; Zu, et al., 2006). In addition, the 
expression of VEGF-C was a significant predictor of poor cause-specific survival in 87 
patients. However, multivariate analysis in the same study showed that VEGF-C was not an 
independent factor and its expression did not correlate with various clinicopathological 
features (Suzuki, et al, 2005). On the other hand, the same analysis showed that the 
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expression of VEGF-C in bladder cancer was a significant and independent predictor of 
pelvic lymph node metastasis. Thus, these reports have demonstrated that VEGF-C plays 
important role in the malignant aggressiveness and its overexpression is associated with 
poor prognosis of patients with bladder cancer. On the other hand, controversy exists 
regarding the prognostic value of VEGF-C expression in bladder cancer (Mylona, et al., 
2006).  
The fact that VEGF-C binds to and stimulates phosphorylation of tyrosine kinase receptor 
VEGFR-3 is well-known. In addition to VEGFR-3, VEGF-C also binds and activates VEGFR-
2, but not VEGFR-1 (Roberts, et al., 2006). Because VEGFR-2 is the major pathway of 
angiogenesis, it is possible that VEGF-C also correlates with angiogenesis in bladder cancer. 
One study of 45 patients with bladder cancer reported that VEGF-C expression did not 
correlate with microvessel density (Zu, et al., 2006). On the other hand, we found that 
VEGF-C expression correlated positively with both MVD and LVD in 126 patients with 
bladder cancer. Another group reported that VEGF-C expression correlated with intra-
tumoral BVD, but not with overall BVD. They also showed that VEGF-C expression 
correlated significantly with both intra-tumoral and peri-tumoral LVD (Afonso, et al., 2009). 
The reasons for these discrepancies are probably related to differences in antibodies used to 
measure MVD and also differences in sample size.  
VEGF-D expression is also reported to be significantly associated with pathological features 
and prognosis of patients with bladder cancer (Miyata et al, 2006; Herrmann, et al., 2007). In 
addition, several studies demonstrated that VEGF-D expression also correlated with tumor 
growth, metastasis, and survival of patients with bladder cancer (Miyata, et al., 2006; 
Herrmann, et al, 2007). However, in comparison with VEGF-C, information regarding 
pathological significance and predictive value of VEGF-D in patients with bladder cancer is 
very limited.  
Similarly, there is a little information on VEGF-B expression in bladder cancer. To our 
knowledge, there is only one study on VEGF-B m-RNA expression in bladder cancer tissues 
(Fauconett, et al., 2009). These authors used Northern blot analysis and reported the lack of 
VEGF-B mRNA expression in 37 bladder cancer specimens.  
2.7 Ang family in cancers including bladder cancer 
Angiopoietin (Ang)-1 and -2 have angiogenic function acting on Tie2 tyrosine kinase 
receptors (Maisonpierre, et al., 1997; Papapetropoulos, et al., 1999). Ang-1 is known as 
stabilizing factor because it helps to maintain and stabilize mature vessels by promoting 
interactions between endothelial cells and neighboring cells including pericytes and smooth 
muscle cells (Maisonpierre, et al., 1997; Papapetropoulos, et al., 1999, 2000). In contrast, Ang-
2 is known as an antagonist to Ang-1 because it is expressed at sites of vascular remodeling 
and acts to destabilize vessels (Maisonpierre, et al., 1997). Interestingly, Ang-2 is reported to 
potentiate angiogenesis in the presence of VEGF, but causes regression of this process in the 
absence of VEGF (Maisonpierre, et al., 1997; Holash, et al., 1999). Thus, the angiopoietin-Tie2 
system, comprising Ang-1, Ang-2, Tie2, and VEGF, seems to be regulated by complex 
mechanisms.  
In bladder cancer, there are conflicting results on the clinical and pathological significance of 
angiopoietin-Tie2 system. One study demonstrated a significant correlation between Ang-2 
protein expression and high stage, high grade tumors, and poor prognosis, whereas Ang-1 
protein expression did not show the same trend (Oka, et al., 2005). It also showed that Ang-2 
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expression was an independent predictor of overall survival in patients with bladder cancer. 
On the other hand, Ang-2 mRNA expression in early stage superficial carcinomas and low 
grade tumors was reported to be significantly higher than in advanced stage muscle 
invasive carcinomas and high grade tumors (Quentin, et al., 2004). In comparison, the same 
study also reported that Ang-1 mRNA was expressed at significantly low levels in low 
grade and early stage tumors compared to high grade or advanced stage tumors. Other 
studies on Ang-1 and Ang-2 demonstrated the presence of significantly higher serum levels 
of Ang-1 in patients with bladder cancer relative to the control; and conversely, Ang-2 and 
Tie2 levels were significantly lower. (Szarvas, et al., 2009). The same study also showed that 
high Tie2 serum level was an independent prognostic factor for metastasis in multivariate 
analysis model that included tumor grade and stage.  
2.8 Limitation of quantification of angiogenesis and lymphangiogenesis 
BVD is often used as a quantitative marker of angiogenesis. The method used for 
quantification was first described after antibodies to factor VIII-related antigen became 
commercially availability; these antibodies were used to immunohistochemically stain blood 
vessels. Since then, various immunohistochemical pan-endothelial markers, such as CD31, 
CD34, von-Willebrand factor, have been used to stain and study blood vessels. CD31, also 
known as PECAM-1 (Platelet Endothelial Cell Adhesion Molecule-1), is a 130 KDa integral 
membrane protein, and is expressed constitutively on the surface of adult and embryonic 
endothelial cells. The CD34 protein is a member of a family of single-pass transmembrane 
proteins expressed on blood vessel endothelial cells (Nielsen & McNagny, 2008). However, 
these markers cannot distinguish between small and large blood vessels (Hassan, et al., 
2002). On the other hand, CD105, also known as endoglin, is a disulphide-linked, 
proliferation-associated, hypoxia-inducible homodynamic cell membrane glycoprotein, and 
is known to be over-expressed in proliferating endothelial cells and is strongly up-regulated 
in endothelial cells of neoplastic tissues compared with normal cells (Fonasanti, et al., 2002; 
Minhajat, et al., 2006). Based on these properties, many recent studies have recommended 
the use of CD105 for evaluation of angiogenesis in tumor tissues because it reflects the 
dynamic status of tumor-related angiogenesis compared to other pan-endothelial markers 
(Sharma, et al., 2005). In fact, so far, CD105 antibody was demonstrated to have a greater 
specificity for tumor vasculature than other pan-endothelial markers, such as CD31, CD34, 
and Factor VIII in a clinical study of colorectal cancer (Saadi, et al., 2004). 
In bladder cancer tissues, several antibodies have been used to evaluate angiogenesis. These 
include factor VIII (Lianes, et al., 1998; Shirotake, et al., 2011), CD31 (Korkolopoulos, et al., 
2001; Afonso, et al., 2009), and CD34 (Shirotake, et al., 2011; Stavropoulos, et al., 2004; 
Ioachim, et al., 2006); whereas CD105 has rarely been used in bladder cancer tissues.  
It is suggested that CD31, CD34, and CD105 are more useful because they efficiently 
recognize small-caliber vessels that are associated with angiogenesis in bladder cancer than 
factor VIII (Santos, et al., 2003). However, this study did not discuss the difference between 
these markers. Thus, to date, there is no ideal antibody to truly reflect the clinical and 
pathological significance of angiogenesis in bladder cancer. To this effect, some investigators 
have doubted the pathological significance and predictive value of BVD in patients with 
bladder cancer (Table 2).  
Similar to angiogenesis, there is no ideal antibody that reflects the significance of 
lymphangiogenesis. In general, three different antibodies such as anti-lymphatic vessel 
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endothelial hyaluronan receptor (LYVE)-1 (Yang, et al., 2011), anti-VEGFR-3 (Zhou et al., 
2011) and anti-D2-40 (Miyata, et al., 2006; Afonso, et al., 2009,) have been used to detect 
lymphatic vessels. However, detailed information on the differences and characteristics of 
each of these factors is not available. Further studies are necessary to discuss the methods of 
quantification and evaluation of lymphangiogenesis in bladder cancer tissues.  
 
 n Antibody Progression Survival Reference year 
NMIBC 35 CD31 No No Korkolopoulou 2001 
NMIBC 66 CD31+CD34+FVIII Yes* – Santos 2003 
NMIBC 109 CD34 Yes** – Stavropoulos 2004 
MIBC 109 FVIII No No Linanes 1998 
MIBC 80 CD31 Yes No Korkolpoulou 2001 
Both 113 CD31+CD34 No Yes Bochener 1995 
Both 148 CD34 No No Ioachim 2006 
Both 42 CD31+FVIII – – Gehani 2011 
NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer; 
FVIII, factor VIII. * In T1/grade 2 patients. ** In grade 3 patients. 
Table 2. Prognostic significance of blood vessel density (BVD)  
3. Conclusion 
Angiogenesis and lymphangiogensis play important roles for tumor growth and 
progression in bladder cancer. VEGF family and Ang family are well known to be associated 
with these phenomenon in bladder cancer. However, other factors and molecules are also 
speculated to regulate them by complex mechanism. So, detailed mechanism of their 
regulations is still fully understood. In addition, further studies are necessary to discuss the 
methods of quantification and evaluation of angiogenesis and lymphangiogenesis in 
bladder cancer tissues.  
4. Acknowledgement  
We are grateful to Mr. Takumi Shimogama, Mr. Yoshikazu Tsuji, Mrs. Miki Yoshimoto, and 
Mrs. Miho M. Kuninaka, for their outstanding support. This manuscript was supported in 
no funding. 
5. References 
Afonso, J.; Santos, L.L.; Amaro, T. et al. (2009). The aggressiveness of urothelial carcinoma 
depends to a large extent on lymphvascular invasion – the prognostic contribution 
of related molecular markers. Histopathology, Vol.55, No.5, (July), pp. 514-524. 
Algaba, F. (2006). Lymphovascular invasion as aprognotic tool for advanced bladder cancer. 
Curr Opin Urol, Vol.16, No.5 (September), pp. 367-371. 
Autiero, M.; Waltenberger, J.; Communi, D. et al. (2003). Role of PIGF in the intra- and 
intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med, 
Vol.9, No.7, (July), pp. 936-943.  
www.intechopen.com
 
Angiogenesis and Lymphangiogenesis in Bladder Cancer 
 
125 
Barleon, B.; Sozzani, S.; Zhou, D. et al. (1996). Migration of human monocytes in response to 
vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. 
Blood, Vol.87, No.8, (April), pp. 3336-3343. 
Campbell, SC.; Volpert, O.V.; Ivanovich, M. et al. (1998). Molecular mediators of 
angiogenesis in bladder cancer. Cancer Res, Vol.58, No.6 (March), pp. 1298-1304.  
Cao, Y.; Linden, P.; Famebo, J. et al. (1998). Vascular endothealil growth factor C induceds 
angiogenesis in vivo. Proc Natl Acd Sci USA, Vol.95, No24. (November), pp. 14389-
14394.  
Carmeliet, P.; Moons, L.; Luttun, A. et al. (2001). Synergism between vascular endothelial 
growth factor and placental growth factor contributes to angiognenesis and plasma 
extravasation in pathological conditions. Nat Med, Vol.7, No.5, (May), pp. 575-583.  
Clauss, M.; Weich, H.; Breier, G. et al. (1996). The vascular endothelial growth factor 
receptor Flt-1 mediates biological activities. Implications for a functional role of 
placenta growth factor in monocyte activation and chemotaxis. J Biol Chem, 
Vol.271, No.30, (July), pp.17629-17634. 
Cursiefen, C.; Chen, L.; Borges, L.P. (2004). VEGF-A stimulates lymphangiogensis and 
hemangiogenesis in inflammatory neovasculalization via macrophage recruitment. 
J Clin Invest, Vol.113, No.7, (April), pp.1040-1050. 
Fauconnet, S.; Bernardini, S.; Lascombe, I. et al. (2009). Expression analysis of VEGF-A and 
VEGF-B: relationship with clinicopathological parameters in bladder cancer. Oncol 
Rep, Vol.21, No.6, (June), pp. 1495-1504. 
Fernández, M.I.; Bolenz, C.; Smith, N.; et al. (2008). Prognostic implications of 
lymphangiogenesis in muscle-invasive transitional cell carcinoma of the bladder. 
Eur Urol, Vol.53, No.3, (March), pp. 571-578. 
Fischer, C.; Mazzone, M.; Jonckx, B. et al. (2008). Flt1 and its ligands VEGFB and PIGF: 
during targets for anti-agniogenic therapy? Nat Rev Cancer, Vol.8, No.12, 
(December), pp. 942-956. 
Folkman, J. (1971). Tumor angiogenesis: Thrapeutic implications. N Engl J Med, Vol.285, 
No.21, (November), pp. 285: 1182-1186. 
Folkman, J. (1992). The role of angiogenesis in tumor growth. Semin Cancer Biol Vol.3, No.2, 
(April), pp. 65-71. 
Fonsatti, E.; Altomonte, M.; Nicotra, M.R. et al. (2003). Endoglin (CD105): a powerful 
therapeutic target on tumor-associated angiognenenic blood vessels. Oncogene, 
Vol.22, No.42, (May), pp. 6557-6563. 
Goddard, J.C.; Sutton, C.D.; Furness, P.N.; et al. (2003). Microvessel density at presentation 
predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 
2003, Vol.9, No.7, (July), pp. 2583-2586. 
Grossfeld, G.D.; Ginsberg, D.A.; Stein, J.P. et al. (1997). Thrombospondin-1 expression in 
bladder cancer: association with p53 alternations, tumor angiogenesis, and tumor 
progression. J Natl Cancer Inst, Vol.89, No.3, (February), pp. 219-227. 
Harada, K.; Sakai, I, Hara, I.; et al. (2005). Prognostic significance of vascular invasion in 
patients with bladder cancer who underwent radical cystectomy. J Urol. Vol.12, 
No.3, (March), pp.250-255. 
Hasan, J.; Byers, R. & Jayson, GC. (2002). Intra-tumoural microvessel density in human solid 
tumours. Br J Cancer, Vol.86, No. 1566 – 1577. 
www.intechopen.com
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
126 
He, Y.; Kozaki, K.; Karpanen, T. et al. (2002). Suppression of tumor lymphangiogensis and 
lymph node metastasis by blocking vascular endothelial growth factor 3 signaling. J 
Natl Cancer Inst, Vol.94, No.11, (June), pp. 819-825. 
Herrmann, E.; Eltze, E.; Bierer, S. et al. (2007). VEGF-C, VEGF-D, and Flt-4 in transitional 
bladder cancer: relationships to clinicopathological parameters and long-term 
survival. Anticancer Res, Vol.27, No.5A, (September-October), pp. 3127-3133.  
Hirakawa, S.; Kodama, S.; Kunstfeld, R. et al. (2005). VEGF-A induces tumor and sentinel 
lymph node lymphangiogensis and promotes lymphatic metastasis. J Exp Med, 
Vol.201, No.7, (April), pp. 1089-1099. 
Hong, Y.K.; Lange-Asschenfeldt, B.; Velasco, P. et al. VEGF-A promotes tissue repair-
associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and 
alpha2beta1 integrins. FASEB J, Vol.18, No.10, (July), pp. 1111-1113. 
Holash, J.; Maisonpierre, P.C.; Olsson, L.E. et al. (1999). Vessel cooption, regression, and 
growth in tumors mediated by angiogenesis and VEGF. Science, Vol.284, No.5422 : 
pp. 1994-1998. 
Jussila, L. & Alitalo, K. (2002). Vascular growth factors and lymphangiogensis. Physiol Rev, 
Vol.82, No.3, (July), pp. 673-700. 
Ioachim, E.; Michael M.C.; Salmas, M.; et al. (2006) Thrombospondin-1 expression in 
urothelial carcinoma: prognostic significance and association with p53 alterations, 
tumour angiogenesis and extracellular matrix components. BMC Cancer Vol. 29, 
No.6, (May), p140. 
Korkolopoulou, P.; Konstantinidou, A.E.; Kavantzas, N.; et al. (2001). Morphometric 
microvascular characteristics predict prognosis in superficial and invasive bladder 
cancer. Virchow Arch (2001) Vol.438, No. 6, (June): 603-611. 
Lawler, J. (2000). The functions of thromboospondin-1 and -2. Curr Opin Cell Biol, Vol.12, 
No.5, (October), pp. 634-640.  
Lianes, P.; Chartytonowicz, E.; Cordon-Cardo, C. et al. (1998). Biomarker study of primary 
nonmetastatic versus metastatic invasive bladder cancer. Clin Cancer Res, Vol.4, 
No.5, (May), pp. 1267-1271. 
Lin, J.; Lalani, A.S.; Harding, T.C., et al. (2005). Inhibition of lymphogenous metastasis using 
adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy 
receptor. Cancer Res, Vol.65, No.15, (August), pp. 6901-6909. 
Luttun, A.; Tjwa, M,; Moons, L. et al. (2002). Revascularization of ischemic tissues by PIGF 
treatment, and inhibition of tumor angiogenesis, arthritis, and atherosclerosis by 
anti-Flt1. Nat Med, Vol.8, No.8, (August), pp. 831-840. 
Maisonpierre, P.C.; Suri, C.; Jones, P.F. et al. (1997). Angiopoietin-2, a natural antagonists for 
Tie 2 that discupts in vivo angiogeensis. Science, Vol.227, No.5322, (July), pp. 55-60. 
Miyata, Y.; Kanda, S.; Ohba, K.; et al. (2006). Lymphangiogenesis and angiogenesis in 
bladder cancer: prognostic implications and regulation by vascular endothelial 
growth factors-A, -C, and -D. Clin Cancer Res Vol.12, No.3 pt 1, (February), pp. 
300-306. 
Mylona, E.; Magkou, C.; Gorantonakis, G. et al. (2006). Evaluation of the vascular 
endothelial growth factor (VEGF)-C role in urothelial carcinomas of the bladder. 
Anticancer Res, Vol.26, No.5A, (Deptember-October), pp. 3567-3571. 
www.intechopen.com
 
Angiogenesis and Lymphangiogenesis in Bladder Cancer 
 
127 
Nagy, J.A.; Vasile, E.; Feng, D. et al. (2002). Vascular permeability factor/vascular 
endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J 
Exp Med, Vol.196, No.11, (December), pp. 1497-1506. 
Nielsen, J.S. & McNagny, K.M. (2008). Novel functions of the CD34 family. J of Cell Science, 
Vol.121, Vol.Pt 22, (November), pp. 3682-3692 
O’Brien, T.; Cranston, D.; Fuggle, S. et al. (1995). Different angiogenic pathways characterize 
superficial and invasive bladder cancer. Cancer Res, Vol.55, No3, (February), pp. 
510-513.  
Oka, N.; Yamamoto, Y.; Takahashi, M. et al. (2005). Expression of angiopoietin-1 and -2, and 
its clinical significance in human bladder cancer. BJU Int, Vol.95, No.4, (March), pp. 
660-773. 
O’Reilly, M.S.; Holmgren, L.; Shing, Y. et al. (1994). Angiostatin: a novel angiogenesis 
inhibitor that medicates the suppression of metastases by a Lewis lung carcinoma. 
Cell, Vol.79, No.2, (October), pp. 315-328. 
O’Reilly, M.S.; Boehm, T.; Shing, Y.; et al. (1997). Endostatin: an endogenous inhibitor of 
angiogenesis and tumor growth. Cell 1997, Vol.88, No.2 (January), pp277-285. 
Papapetropoulos, A.; Garcia-Cardena, G.; Dengler, T.J. et al. (1999), Direct actions of 
angiopoietin-1 on human endothelium: evidence for network stabilization, cell 
survival, and interaction with other angiogenic growth factors. Lab Invest, Vol.79, 
No.2, (February), pp. 213-223. 
Papapetropoulos, A.; Fulton, D.; Mahboubi, K. et al. (2000). Angiopoietin-1 inhibits 
endothelial cell apoptosis via the Akt/survival pathway. J Biol Chem, Vol.275, 
No.13, (March), pp. 9102-9105. 
Pepper, M.S. (2001). Lymphangiogenesis and tumor metastasis: myth or reality? Clin Cancer 
Res, Vol.7, No.3, (March): pp.462-468. 
Roberts, N.; Kloos, B.; Cassella, M. et al. (2006). Inhibition of VEGFR-3 activation with the 
antagonistic antibody more potentially suppresses lymph node and distant 
metastases than inactivation of VEGFR-2. Cancer Res, Vol.66, No.5, (March), pp. 
2650-2657. 
Quentin, T.; Schlott, T.; Korabiowska, M. et al. (2004). Alternation of the vascular endothelial 
growth factor and angiopoientin-1 and -2 pathways in transitional cell carcinoma of 
the urinary bladder asscoaited with tumor progression. Anticancer Res, Vol.24, 
No.5A, (September-October), pp. 2745-2756. 
Santos, L.; Costa, C.; Pereira, S. et al. (2003). Neovascularisation is a prognostic factor of 
early recurrence in T1/G2 urothelial bladder cancer. Ann Oncol, Vol.14, No.9, 
(September): pp.1419-1424.  
Sharma, S.; Sharma, M.C. & Sarkar, C. (2005). Morphology of angiogenesis in human cancer: 
a conceptual overview, histoprognostic perspective and significance of 
neoangiogenesis. Histopathology, Vol.46, No.5, pp. 481-489. 
Shibuya, M. & Claesson-Welsh L. (2006). Sinal transduction by VEGF receptors in regulation 
of angiogenesis and lymphangiogensis. Exp Cell Res, Vol.312, No.5, (March), pp. 
549-560. 
Shirotake, S.; Miyajima, A.; Kosaka, T. et al. (2011). Angiotensin II type 1 receptor expression 
and microvessel density in human bladder cancer. Urology, Vol.77, No.4, (April), 
1009.e19pe25. 
www.intechopen.com
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
128 
Skobe, M.; Hawighorst, T.; Jackson, D.G., et al. (2001). Induction of tumor lymphangiogensis 
by VEGF-C promotes breast cancer metastasis. Nat Med, Vol.7, No.2, (February), 
pp. 192-198. 
Stacker SA, Caesar C, Baldwin ME, et al. (2001). VEGF-D promotes the metastatic spread of 
tumor cells via the lymphatics. Nat Med, Vol.7, No.2, (February), pp. 186-191. 
Stavropoulos, N.E.; Bouropoulos, C.; Ioachim, I.E.; et al. (2004). Prognostic significance of 
angiogenesis in superficial bladder cancer. Int Urol Nephrol Vol.36, No.2, : pp. 163-
167. 
Streeter, E.H. & Harris, A.L. (2002). Angiogenesis in bladder cancer – prognostic marker and 
target for further therapy. Surg Oncol Vol.11, No.1-2 (March): pp. 85-100. 
Szarvas, T.; Jäger, T.; Droste, F. et al. (2009). Serum levels of angiogenic factors and their 
prognostic releavance in bladder cancer. Pathol Oncol Res, Vol.15, No.2, (June), pp. 
193-201. 
Takahashi, H. & Shibuya, M. (2005). The vascular endothelial growth factor (VEGF)/VEGF 
receptor system and its role under physiological and pathological conditions. Clin 
Sci (Lond), Vol.109, No. 3, pp. 227-241. 
Yang, H.; Kim, C.; Kim, M-J. et al. (2011). Soluble vascular endothelial growth factor 
receptor-3 suppresses lymphangiogensis and lymphatic metastasis in bladder 
cancer. Mol Cancer, Vol.10, No.10, (April), pp. 36-48.  
Zhou, M.; He, L.; Zu, X. et al. Lymphatic vessel density as a predictor of lymph node 
metastasis and its relationship with prognosis in urothelial carcinoma of the 
bladder. BJU Int, in press. 
Zu, X.; Tang, Z.; Li, Y. et al. (2006). Vascular endothelial growth factor-C expression in 
bladder transitional cell cancer and its relationship to lymph node metastasis. BJU 
Int, Vol.98, No.5, (November), pp. 1090-1093. 
www.intechopen.com
Bladder Cancer - From Basic Science to Robotic Surgery
Edited by Dr. Abdullah Canda
ISBN 978-953-307-839-7
Hard cover, 460 pages
Publisher InTech
Published online 01, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is an invaluable source of knowledge on bladder cancer biology, epidemiology, biomarkers,
prognostic factors, and clinical presentation and diagnosis. It is also rich with plenty of up-to-date information,
in a well-organized and easy to use format, focusing on the treatment of bladder cancer including surgery,
chemotherapy, radiation therapy, immunotherapy, and vaccine therapy. These chapters, written by the experts
in their fields, include many interesting, demonstrative and colorful pictures, figures, illustrations and tables.
Due to its practicality, this book is recommended reading to anyone interested in bladder cancer.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Yasuyoshi Miyata, Hideki Sakai and Shigeru Kanda (2012). Angiogenesis and Lymphangiogenesis in Bladder
Cancer, Bladder Cancer - From Basic Science to Robotic Surgery, Dr. Abdullah Canda (Ed.), ISBN: 978-953-
307-839-7, InTech, Available from: http://www.intechopen.com/books/bladder-cancer-from-basic-science-to-
robotic-surgery/angiogenesis-and-lymphangiognesis-in-bladder-cancer
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
